Currently, a number of clinical phase II and phase III studies are ongoing to evaluate the clinical benefit of combining HER2-targeted approaches with CDK4/6 inhibitors for treating HER2-positive advanced breast cancer. This evidence concerns the gene ERBB2 and breast cancer.